Details of the Drug-Related molecule(s) Interaction Atlas

L-659989 Drug Info

L-659989; 113787-28-3; L-659,989; L659989; L 659989; CHEMBL37781; SCHEMBL6154076; GTPL3426; DTXSID70433028; BDBM50002829; ZINC13650944; FT-0670693; L-662,418; L-659,989, (+); (2S,5S)-2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)oxolane; (2R,5R)-rel-Tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan; trans-( inverted exclamation markA)-Tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan

Cross-matching ID

PubChem CID

9934870

CAS Number

CAS 113787-28-3

TTD Drug ID

DMLENQ7

General Information of Drug (ID: DMLENQ7)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Platelet-activating factor receptor (PTAFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ticlopidine	DMO946V	Acute coronary syndrome	BA41	Approved	[2]
RUPATADINE	DMBPN7T	N. A.	N. A.	Phase 4	[3]
ISRAPAFANT	DMP61YB	Asthma	CA23	Phase 3	[4]
CMI-392	DM1NCUY	Psoriasis vulgaris	EA90	Phase 2	[5]
Lexipafant	DMZ2YBE	Nerve injury	ND56.4	Phase 2	[6]
YM-264	DMAZNVX	Sepsis	1G40-1G41	Phase 2	[7]
Dersalazine	DMH96JW	Inflammatory bowel disease	DD72	Phase 2	[8]
60P002	DMHBN8X	Dengue	1D20-1D2Z	Phase 2	[9]
PegCNTF	DMW7VGZ	Obesity	5B81	Phase 1	[10]
FOROPAFANT	DML1DGP	Asthma	CA23	Discontinued in Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Platelet-activating factor receptor (PTAFR)	TTQL5VC	PTAFR_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,... J Med Chem. 1992 Sep 18;35(19):3474-82.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
4	Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40.
5	Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
6	Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9.
7	Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.
8	The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740.
9	Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals.
10	Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21.
11	Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51.